Biotechnology company AbCellera (Nasdaq: ABCL) on Monday reported positive topline Phase 2 results for ABCL635, an investigational neurokinin 3 receptor antagonist antibody being developed as a non-hormonal, long-acting treatment for moderate-to-severe vasomotor symptoms associated with menopause.

The trial met its primary efficacy endpoints, with a single 600mg dose producing statistically significant reductions in both the frequency and severity of symptoms at week four compared with placebo. Symptom frequency fell by 83% from baseline compared with 33% for placebo, while severity declined by 58% compared with 12%.

ABCL635 also significantly improved sleep and patient global impression of change. The treatment was well tolerated, with no serious or severe adverse events or discontinuations due to adverse events; the most common adverse events were headache, fatigue and injection site reactions.